

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2016 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the following entities:
 - i) Alivira Animal Health Australia Pty Ltd;
 - ii) Alivira Animal Health Limited, Ireland;
 - iii) Alivira Animal Health Limited, India;
 - iv) Alivira Saude Animal Brasil Participacoes Ltda;
 - v) Alivira UA Limited;

W,

Deloitte Haskins & Sells

- vi) Comercial Vila Veterinaria de Lleida S.L;
- vii) Elysian Life Sciences Private Limited;
- viii) Fendigo BV;
- ix) Fendigo SA;
- x) Interchange Veterinária Indústria E Comércio Ltda;
- xi) Laboratorios Karizoo, S.A;
- xii) Laboratorios Karizoo, S.A. De C.V. (Mexico);
- xiii) N-Vet AB;
- xiv) Naari Pharma Private Limited;
- xv) Phytotherapeutic Solutions S.L;
- xvi) Provet Veteriner Urunleri Sanayi ve Ticaret A.S;
- xvii) SeQuent Antibiotics Private Limited;
- xviii) SeQuent Global Holdings Limited;
- xix) SeQuent Penems Private Limited;
- xx) SeQuent Pharmaceuticals Private Limited;
- xxi) SeQuent Research Limited;
- xxii) Sequent Scientific Pte. Ltd;
- xxiii) Topkim-Topkapi Ilac Premiks San. ve Tic. A.S and
- xxiv) Vila Viña Participacions S.L;

4. We did not review the interim financial results of eleven subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs.13,981.50 lakhs and Rs.32,621.60 lakhs for the quarter and nine months ended December 31, 2016, respectively, and total loss of Rs.865.10 lakhs and Rs.478.20 lakhs and Total comprehensive loss of Rs.865.10 lakhs and Rs.478.20 lakhs for the quarter and nine months ended December 31, 2016, respectively, as considered in the consolidated unaudited financial results.


These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.

5. The consolidated unaudited financial results includes the interim financial results of twelve subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs.1,227.24 lakhs and Rs.2,762.27 lakhs for the quarter and nine months ended December 31, 2016, respectively, and total loss after tax of Rs.124.10 lakhs and Rs.962.71 lakhs and Total comprehensive loss of Rs.124.17 lakhs and Rs.962.78 lakhs for the quarter and nine months ended December 31, 2016, respectively, as considered in the consolidated unaudited financial results.

Deloitte Haskins & Sells

6. Based on our review conducted as stated above and based on the consideration of the reports of the other auditors referred to in paragraph 4 above and except for the possible effects of the matter described in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



Sathya P. Koushik
Partner
(Membership No. 206920)

MUMBAI, February 10, 2017
SPK/JKS/2017

Sequent

Proven Ability in Life Sciences

SEQUENT SCIENTIFIC LIMITED

(Rs. in Lakhs)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2016

Particulars	3 months ended 31-Dec-2016	Preceding 3 months ended 30-Sept-2016	Corresponding 3 months ended in the previous year 31-Dec 2015	Year to date figures for the current period ended 31-Dec 2016	Year to date figures for the previous period ended 31-Dec 2015
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED
1. Income from operations					
a. Sales / income from operations (inclusive of excise duty)	27,480.06	25,204.74	14,937.20	70,549.80	45,737.67
b. Other operating income	219.00	151.70	580.95	578.30	707.57
Total income from operations	27,699.06	25,356.44	15,518.15	71,128.10	46,445.24
2. Expenses					
a. Cost of materials consumed	10,788.70	12,870.70	4,545.50	30,811.40	15,234.70
b. Purchase of stock-in-trade	1,782.30	1,043.10	2,364.40	4,925.00	7,175.20
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,438.30	(999.40)	581.50	36.30	537.40
d. Excise duty on sale of goods	391.46	314.14	263.50	1,097.50	937.10
e. Employee benefits expenses	3,949.20	3,676.60	2,341.13	10,724.20	6,166.46
f. Depreciation and amortisation expenses	1,833.00	1,647.40	1,097.67	4,904.60	2,954.74
g. Other expenses	7,508.60	6,406.80	4,535.33	18,928.10	11,708.84
Total expenses	27,691.56	24,959.34	15,729.03	71,227.10	44,714.44
3. Profit/(loss) from operations before other income, finance costs and exceptional items (1-2)	7.50	397.10	(210.88)	(99.00)	1,730.80
4. Other income	550.40	329.80	288.76	1,113.10	1,134.00
5. Profit/(loss) from ordinary activities before finance cost and exceptional items (3+4)	557.90	726.90	77.88	1,014.10	2,864.80
6. Finance cost	1,213.30	941.40	840.20	3,029.70	2,790.70
7. Profit/(loss) from ordinary activities after finance cost but before exceptional items (5+6)	(655.40)	(214.50)	(762.32)	(2,015.60)	74.10
8. Exceptional items- Expense/(Income)	-	-	-	-	-
9. Profit/(loss) from ordinary activities before tax (7+8)	(655.40)	(214.50)	(762.32)	(2,015.60)	74.10
10. Tax expense	165.00	230.00	79.87	435.80	255.67
11. Net profit/(loss) for the period (11+12)	(820.40)	(444.50)	(842.19)	(2,451.40)	(181.57)
12. Share of profit/(loss) of associates	-	-	-	-	-
13. Non-controlling interest	(533.10)	70.70	248.99	(624.00)	369.62
14. Net profit/(loss) after taxes, minority interest and share of profit/(loss) of associates (11+12+13)	(287.30)	(515.20)	(1,091.18)	(1,827.40)	(551.19)
15. Other comprehensive income	1,916.24	(3,875.03)	3,110.41	(887.50)	21,765.16
16. Total comprehensive income	1,628.94	(4,390.23)	2,019.23	(2,714.90)	21,213.97
17. Paid-up equity share capital (Face Value per share Rs.2 each)	4,874.72	4,874.72	4,764.72	4,874.72	4,764.72
18. Earnings per share (of Rs. 2 each) (not-annualised)					
Basic (Rs.)	(0.12)	(0.22)	(0.50)	(0.77)	(0.28)
Diluted (Rs.)	(0.12)	(0.22)	(0.50)	(0.77)	(0.28)
See accompanying note to the financial results					



Notes:

1. The unaudited financial results has been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on February 10, 2017. The statutory auditors have carried out limited review of the financial results.

2. Segment Results

The Company has identified Pharmaceuticals and Analytical Services as its business segments. Segments have been identified taking in to account the nature of products, the differing risks and returns, the organisational structure and the internal reporting system.

(Rs. in Lakhs)					
Particulars	3 months ended 31-Dec-2016	Preceding 3 months ended 30-Sept-2016	Corresponding 3 months ended in the previous year 31-Dec 2015	Year to date figures for the current period ended 31-Dec 2016	Year to date figures for the previous period ended 31-Dec 2015
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED
1.Segment Revenue					
a) Pharmaceuticals	27,584.96	25,164.94	15,343.67	70,843.00	45,865.47
b) Analytical Services	114.10	191.50	174.48	485.10	579.77
Total	27,699.06	25,356.44	15,518.15	71,128.10	46,445.24
Less : Inter Segment Revenue	-	-	-	-	-
Net Sales /Income from Operations	27,699.06	25,356.44	15,518.15	71,128.10	46,445.24
2.Segment Results					
Profit or (Loss) before Tax and Interest from Each Segment					
a) Pharmaceuticals	(140.40)	325.73	(184.45)	(362.69)	1,667.59
b) Analytical Services	147.90	71.37	(26.43)	263.69	63.21
Total	7.50	397.10	(210.88)	(99.00)	1,730.80
Less (i) Finance Cost	1,213.30	941.40	840.20	3,029.70	2,790.70
(ii) Other unallocable expenditure net off unallocable (income)	(550.40)	(329.80)	(288.76)	(1,113.10)	(1,134.00)
Total Profit / (Loss) Before Tax	(655.40)	(214.50)	(762.32)	(2,015.60)	74.10
3.Segment Assets					
a) Pharmaceuticals	1,36,516.75	1,37,607.81	1,01,079.52	1,36,516.75	1,01,079.52
b) Analytical Services	1,958.85	2,230.79	1,766.43	1,958.85	1,766.43
c) Unallocated	42,891.50	42,119.30	49,922.31	42,891.50	49,922.31
Total	1,81,367.10	1,81,957.90	1,52,768.26	1,81,367.10	1,52,768.26
4.Segment Liabilities					
a) Pharmaceuticals	80,816.89	81,371.21	47,936.43	80,816.89	47,936.43
b) Analytical Services	1,703.11	1,494.59	1,265.61	1,703.11	1,265.61
c) Unallocated	1,478.90	1,198.30	1,073.87	1,478.90	1,073.87
Total	83,998.90	84,064.10	50,275.91	83,998.90	50,275.91

3. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July 2016. The Company has opted to avail the relaxation provided by SEBI in respect of disclosure requirements for corresponding figures for the earlier periods. The results for the quarter and period months ended December 31, 2015 have been recasted to be Ind AS compliant.

4. Reconciliation of net profit for the quarter and nine months ended December 31, 2015 as reported earlier in accordance with previous Indian GAAP and now being reported in accordance with Ind AS, as stated in Note 3 above is as follows:

(Rs. in Lakhs)		
Net profit reconciliation	Quarter ended 31-Dec 2015	Year to date figures for the previous period ended 31-Dec 2015
Net profit / (loss) after tax as per previous GAAP (Indian GAAP)	(1,125.37)	(819.37)
Add/(Less): Fair value of mutual funds	(26.94)	239.18
Add/(Less): Amortization of leasehold land	28.00	84.00
Add/(Less): Amortisation of intangibles	18.75	56.26
Add/(Less): Fair value of derivatives	35.79	3.50
Add/(Less): Deferred tax adjustments	0.95	0.95
Add/(Less): Share of Non-Controlling Interest	0.14	0.14
Add/(Less): Exchange loss on contingent consideration	-	(48.86)
Add/(Less): Employee benefit expenses (share based payments, Actuarial gain/loss)	(6.83)	(25.36)
Add/(Less): Others	(15.67)	(41.63)
Net profit / (loss) after tax as per Ind AS [A]	(1,091.18)	(551.19)
Other Comprehensive Income (OCI):		
Add/(Less): Exchange differences on translation of foreign operation	306.28	(73.42)
Add/(Less): Re-measurement gains/ (losses) on defined benefit plans	(7.85)	(23.55)
Add/(Less): Fair value of equity investment through OCI	2,811.98	21,862.13
Sub-total [B]	3,110.41	21,765.16
Total comprehensive income for the period [A+B]	2,019.23	21,213.97

5. Information on Standalone Results:

(Rs. in Lakhs)					
Particulars	3 months ended 31-Dec-2016	Preceding 3 months ended 30-Sept-2016	Corresponding 3 months ended in the previous year 31-Dec 2015	Year to date figures for the current period ended 31-Dec 2016	Year to date figures for the previous period ended 31-Dec 2015
Total Income from operations (net)	10,503.46	9,456.22	8,780.29	28,981.00	31,294.10
Profit before Tax	(67.85)	(64.54)	257.90	(324.09)	1,070.35
Profit after Tax	(67.85)	(64.54)	257.90	(324.09)	1,070.35
Total comprehensive income	1,814.74	(4,115.79)	3,070.58	(1,137.54)	22,934.58

6. The Board of Directors of the Company at their meeting held on February 3, 2017 have given in principle approval for de-merger of Human API business, subject to the approval from the shareholders, applicable laws, consents, permissions and sanctions as may be necessary. The Company's Human API business is proposed to be de-merged into a new listed entity. The above decision is in line with the Company's focus on value creation in Animal Healthcare.



7. The Board of Directors of the Company at their meeting held on February 3, 2017 have approved the divestment of Women healthcare business from a partially owned subsidiary of the Company to a promoter group company, subject to the approval of non-promoter shareholders of the company through a postal ballot. The company has entered into a Term Sheet for such divestment and accordingly Indo Phyto Chemicals Private Limited has been identified as a discontinuing operation. The results of such discontinuing operations included in the results are as given below:

Particulars	(Rs. in Lakhs)		
	3 months ended 31-Dec-2016	Preceding 3 months ended 30-Sept-2016	Year to date figures for the current period ended 31-Dec 2016
	UNAUDITED	UNAUDITED	UNAUDITED
Income from Operations	1,453.54	2,407.14	5,061.05
Total Expenses	1,928.50	2,350.80	5,863.37
Profit before other income, finance cost & exceptional items	(474.96)	56.34	(802.32)
Other Income	0.10	-	13.63
Profit before finance cost & exceptional items	(474.86)	56.34	(788.69)
Finance cost	265.80	94.01	444.41
Profit before exceptional items	(740.66)	(37.67)	(1,233.10)
Exceptional items	-	-	-
Profit/ (Loss) before tax	(740.66)	(37.67)	(1,233.10)
Tax expense	-	-	(8.56)
Profit/ (Loss) for the period	(740.66)	(37.67)	(1,224.54)
Net Profit/Loss from these operation attributable to:-			
- Equity holder of the parent	(377.89)	(19.22)	(624.76)
- Non-controlling Interests	(362.77)	(18.45)	(599.78)


8. The Shareholders of Sequent Global Holdings Limited ('SGHL'), a wholly owned subsidiary of the Company, have approved winding up of SGHL, vide a resolution dated 4th Nov 2016.

9. The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited


Manish Gupta
Managing Director

Place : Thane
Date : February 10, 2017



Deloitte Haskins & Sells

Chartered Accountants
Deloitte Centre
Anchorage II
100/2 Richmond Road
Bengaluru - 560 025
India

Tel: +91 (080) 6627 6000
Fax: +91 (080) 6627 6013

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SEQUENT SCIENTIFIC LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SEQUENT SCIENTIFIC LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.


2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

W,

Deloitte Haskins & Sells

3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



Sathya P. Koushik
Partner
(Membership No. 206920)

MUMBAI, February 10, 2017
SPK/JKS/2017

Sequent

Proven Ability In Life Sciences
SEQUENT SCIENTIFIC LIMITED

(Rs. in Lakhs)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2016					
Particulars	3 MONTHS ENDED			9 MONTHS ENDED	
	31-Dec-16	30-Sep-16	31-Dec-15	31-Dec-16	31-Dec-15
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED
1. Income from operations					
a Sales / income from operations (inclusive of excise duty)	10,449.26	9,317.74	8,172.48	28,623.90	30,204.63
b Other operating income	54.20	138.48	607.81	357.10	1,089.47
Total income from operations	10,503.46	9,456.22	8,780.29	28,981.00	31,294.10
2. Expenses					
a Cost of materials consumed	4,390.24	5,478.87	3,560.10	14,406.95	11,613.70
b Purchase of stock-in-trade	1,506.29	55.58	600.50	1,820.79	4,802.50
c Changes in inventories of finished goods, work-in-progress and stock-in-trade	235.86	(451.41)	(143.30)	(237.36)	751.70
d Excise duty on sale of goods	351.22	274.90	263.50	990.79	937.10
e Employee benefits expenses	1,155.12	1,147.85	984.81	3,442.06	2,906.34
f Depreciation and amortisation expenses	630.17	610.99	561.57	1,809.48	1,609.42
g Other expenses	2,473.94	2,728.71	2,719.27	7,749.38	7,474.27
Total expenses	10,742.84	9,845.49	8,546.45	29,982.09	30,095.03
3. Profit/(loss) from operations before other income, finance costs and exceptional items (1-2)	(239.38)	(389.27)	233.84	(1,001.09)	1,199.07
4. Other income	390.90	501.18	294.76	1,288.80	1,129.98
5. Profit/(loss) from ordinary activities before finance cost and exceptional items (3±4)	151.52	111.91	528.60	287.71	2,329.05
6. Finance cost	219.37	176.45	270.70	611.80	1,258.70
7. Profit/(loss) from ordinary activities after finance cost but before exceptional items (5±6)	(67.85)	(64.54)	257.90	(324.09)	1,070.35
8. Exceptional items- expense/(income)	-	-	-	-	-
9. Profit/(loss) from ordinary activities before tax (7±8)	(67.85)	(64.54)	257.90	(324.09)	1,070.35
10. Tax expense	-	-	-	-	-
11. Net profit/(loss) from ordinary activities after tax (9±10)	(67.85)	(64.54)	257.90	(324.09)	1,070.35
12. Other comprehensive income	1,882.59	(4,051.25)	2,812.68	(813.45)	21,864.23
13. Total comprehensive income (11±12)	1,814.74	(4,115.79)	3,070.58	(1,137.54)	22,934.58
14. Paid-up equity share capital (Face Value per share Rs. 2 each)	4,874.72	4,874.72	4,764.72	4,874.72	4,764.72
15 Earnings per share (of Rs. 2 each) (not-annualised)					
Basic (Rs.)	(0.03)	(0.03)	0.12	(0.14)	0.54
Diluted (Rs.)	(0.03)	(0.03)	0.11	(0.14)	0.50
See accompanying note to the financial results					



Notes:

- The unaudited financial results has been reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on February 10, 2017. The statutory auditors have carried out limited review of the financial results.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July 2016. The Company has opted to avail the relaxation provided by SEBI in respect of disclosure requirements for corresponding figures for the earlier periods. The results for the quarter and period ended December 31, 2015 have been recasted to be Ind AS compliant.
- Reconciliation of net profit for the quarter and nine months ended December 31, 2015 as reported earlier in accordance with previous Indian GAAP and now being reported in accordance with Ind AS, as stated in Note 2 above is as follows:

	(Rs. in Lakhs)	
Net profit reconciliation	Quarter ended 31-Dec-2015	Nine months ended 31-Dec-2015
Net profit / (loss) after tax as per previous GAAP (Indian GAAP)	253.30	874.90
Add/(Less): Fair value of mutual funds	(26.94)	239.18
Add/(Less): Fair value of derivatives	46.64	7.01
Add/(Less): Employee benefit expenses (share based payments, Actuarial gain/loss)	(15.10)	(50.74)
Net profit / (loss) after tax as per Ind AS [A]	257.90	1,070.35
Other Comprehensive Income (OCI):		
Add/(Less): Re-measurement gains/ (losses) on defined benefit plans	0.70	2.10
Add/(Less): Fair value of equity investment through OCI	2,811.98	21,862.13
Sub-total [B]	2,812.68	21,864.23
Total comprehensive income for the period [A+B]	3,070.58	22,934.58

- The Board of Directors of the Company at their meeting held on February 3, 2017 have given in principle approval for de-merger of Human API business, subject to the approval from the shareholders, applicable laws, consents, permissions and sanctions as may be necessary. The Company's Human API business is proposed to be de-merged into a new listed entity. The above decision is in line with the Company's focus on value creation in Animal Healthcare.
- The Board of Directors of the Company at their meeting held on February 3, 2017 have approved the divestment of Women healthcare business, a partially owned subsidiary of the Company to a promoter group company, subject to the approval of non-promoter shareholders of the company through a postal ballot.
- The Shareholders of Sequent Global Holdings Limited ('SGHL'), a wholly owned subsidiary of the Company, have approved winding up of SGHL, vide a resolution dated 4th November 2016.
- The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- The previous period figures have been regrouped wherever necessary to correspond with the current period disclosure.

For Sequent Scientific Limited


Manish Gupta
Managing Director

Place : Thane

Date : February 10, 2017

